A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above

Recruiting now · Phase 1

Conditions studied: Influenza

In brief

This is a randomized, blinded, controlled phase I clinical trial with a total of 120 participants aged ≥ 60 years. Experimental group: Influenza virus split vaccine (0.7mL/vial), control group 1: Influenza virus split vaccine, control group 2: placebo group. The three groups were recruited at a ratio of 1:1:1, and 40 individuals were randomly vaccinated in each group. Each person was injected with one dose of the vaccine into the deltoid muscle of the upper arm. Participants in each study group are required to undergo laboratory indicator tests before and on the 4th day after vaccination.

Key facts

Study ID
NCT07302256
Run by
Shanghai Institute Of Biological Products
People needed
120
Starts
2025-12-16
Expected to finish
2026-08-31
Last updated by the study team
2026-01-14

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.